Published in PLoS One on June 22, 2016
Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med (2011) 6.42
Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol (1990) 5.66
Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. Council of State and Territorial Epidemiologists; AIDS Program, Center for Infectious Diseases. MMWR Morb Mortal Wkly Rep (1987) 3.66
Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. AIDS (2007) 3.19
Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol (2007) 2.93
Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med (2002) 2.52
Determinants of survival in AIDS patients on antiretroviral therapy in a rural centre in the Far-North Province, Cameroon. Trop Med Int Health (2008) 2.28
Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology (2003) 1.92
Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med (1998) 1.85
Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydranize metabolites. Clin Pharmacol Ther (1975) 1.75
Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection. Thorax (2006) 1.60
Systematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection. Antimicrob Agents Chemother (2010) 1.51
HIV-associated tuberculosis: diagnostic and treatment challenges. Semin Respir Crit Care Med (2008) 1.26
CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis. Eur J Clin Pharmacol (2006) 1.25
Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients. PLoS One (2011) 1.17
Association of slow N-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil. Eur J Clin Pharmacol (2008) 1.08
Incidence of and risk factors for severe liver toxicity in HIV-infected patients on anti-tuberculosis treatment. Int J Tuberc Lung Dis (2007) 1.04
Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients. Mem Inst Oswaldo Cruz (2011) 1.04
Inferring haplotypes at the NAT2 locus: the computational approach. BMC Genet (2005) 0.93
A prospective study of antituberculous drug-induced hepatotoxicity in an area endemic for liver diseases. Hepatol Int (2008) 0.92
Pharmacogenetic study of drug-metabolising enzyme polymorphisms on the risk of anti-tuberculosis drug-induced liver injury: a meta-analysis. PLoS One (2012) 0.91
Nutrition and immune function in human immunodeficiency virus infection. Proc Nutr Soc (1999) 0.91
Anti-tuberculosis drug induced hepatotoxicity among TB/HIV co-infected patients at Jimma University Hospital, Ethiopia: nested case-control study. PLoS One (2013) 0.91
Underreporting of the tuberculosis and AIDS comorbidity: an application of the linkage method. Rev Saude Publica (2011) 0.90
Hepatotoxicity in patients co-infected with tuberculosis and HIV-1 while receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and rifampicin-containing anti-tuberculosis regimen. Southeast Asian J Trop Med Public Health (2011) 0.88
Prevalence, drug-induced hepatotoxicity, and mortality among patients multi-infected with HIV, tuberculosis, and hepatitis virus. Int J Infect Dis (2014) 0.84
Evaluation of patterns of liver toxicity in patients on antiretroviral and anti-tuberculosis drugs: a prospective four arm observational study in ethiopian patients. PLoS One (2014) 0.83
Association of N-acetyltransferase 2 and cytochrome P450 2E1 gene polymorphisms with antituberculosis drug-induced hepatotoxicity in Western India. J Gastroenterol Hepatol (2013) 0.82
Association of NAT2, GST and CYP2E1 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity. Tuberculosis (Edinb) (2014) 0.82
N-acetyl transferase 2 and cytochrome P450 2E1 genes and isoniazid-induced hepatotoxicity in Brazilian patients. Int J Tuberc Lung Dis (2013) 0.82
Prevalence and risk factors of anti-tuberculosis drug-induced hepatitis in Malaysia. Singapore Med J (2008) 0.81
[Tuberculosis in patients with HIV infection]. An Sist Sanit Navar (2007) 0.80
Genetic interaction between NAT2, GSTM1, GSTT1, CYP2E1, and environmental factors is associated with adverse reactions to anti-tuberculosis drugs. Mol Diagn Ther (2012) 0.80
Antituberculosis drug-induced hepatotoxicity: a comparison between patients with and without human immunodeficiency virus seropositivity. Rev Soc Bras Med Trop (2010) 0.79
Reversal of cachexia in patients treated with potent antiretroviral therapy. AIDS Read (2000) 0.79
The role of cigarette smoking and liver enzymes polymorphisms in anti-tuberculosis drug-induced hepatotoxicity in Brazilian patients. Tuberculosis (Edinb) (2014) 0.78
Serological markers of hepatitis B and C in patients with HIV/AIDS and active tuberculosis. J Med Virol (2015) 0.75